{"transactions":[{"id":865635,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":63177,"kind":"person","name":"Plavsic Mark","position":1,"cik":"0001868719","reported_name":"Plavsic Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-03T21:05:55.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":112661,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date."}],"balance_after":112661,"derivative":{"exercise_price":6.14,"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":112661},"source":{"system":"sec-edgar","filing":"0001193125-26-088158","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501796/000119312526088158/ownership.xml","form_type":"4"}},{"id":865634,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":63177,"kind":"person","name":"Plavsic Mark","position":1,"cik":"0001868719","reported_name":"Plavsic Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2026-03-03T21:05:55.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":62339,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit (\"RSU\") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date."}],"balance_after":243736,"source":{"system":"sec-edgar","filing":"0001193125-26-088158","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501796/000119312526088158/ownership.xml","form_type":"4"}},{"id":900410,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":63177,"kind":"person","name":"Plavsic Mark","position":1,"cik":"0001868719","reported_name":"Plavsic Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2026-02-18T00:47:51.000Z","date":"2026-02-17","kind":"sale","planned":false,"acquired":false,"shares":15890,"price":5.05,"value":80244.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.04 to $5.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":181397,"source":{"system":"sec-edgar","filing":"0001193125-26-055497","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501796/000119312526055497/ownership.xml","form_type":"4"}},{"id":1017457,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":63177,"kind":"person","name":"Plavsic Mark","position":1,"cik":"0001868719","reported_name":"Plavsic Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2025-10-16T21:44:01.000Z","date":"2025-10-16","kind":"sale","planned":false,"acquired":false,"shares":12169,"price":6.35,"value":77273.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."}],"balance_after":197287,"source":{"system":"sec-edgar","filing":"0001193125-25-241622","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501796/000119312525241622/ownership.xml","form_type":"4"}},{"id":1263322,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":63177,"kind":"person","name":"Plavsic Mark","position":1,"cik":"0001868719","reported_name":"Plavsic Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2025-02-19T00:31:27.000Z","date":"2025-02-18","kind":"sale","planned":false,"acquired":false,"shares":2151,"price":7.75,"value":16670.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."}],"balance_after":209456,"source":{"system":"sec-edgar","filing":"0000950170-25-022655","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501796/000095017025022655/ownership.xml","form_type":"4"}},{"id":1284004,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":63177,"kind":"person","name":"Plavsic Mark","position":1,"cik":"0001868719","reported_name":"Plavsic Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-04T22:52:07.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":59525,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option vest as follows: 25% of the shares vest on February 3, 2026 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date."}],"balance_after":59525,"derivative":{"exercise_price":7.68,"expiration_date":"2035-02-02","underlying":"Common Stock","underlying_shares":59525},"source":{"system":"sec-edgar","filing":"0000950170-25-013829","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501796/000095017025013829/ownership.xml","form_type":"4"}},{"id":1284003,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":63177,"kind":"person","name":"Plavsic Mark","position":1,"cik":"0001868719","reported_name":"Plavsic Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2025-02-04T22:52:07.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":90475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit (\"RSU\") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on February 15, 2026, subject to the Reporting Person's continued service as of each such vesting date."}],"balance_after":211607,"source":{"system":"sec-edgar","filing":"0000950170-25-013829","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501796/000095017025013829/ownership.xml","form_type":"4"}},{"id":1385720,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":63177,"kind":"person","name":"Plavsic Mark","position":1,"cik":"0001868719","reported_name":"Plavsic Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2024-10-17T01:25:42.000Z","date":"2024-10-16","kind":"sale","planned":false,"acquired":false,"shares":7383,"price":9.85,"value":72722.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the Reporting Person."}],"balance_after":121132,"source":{"system":"sec-edgar","filing":"0000950170-24-115150","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501796/000095017024115150/ownership.xml","form_type":"4"}},{"id":2056410,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":63177,"kind":"person","name":"Plavsic Mark","position":1,"cik":"0001868719","reported_name":"Plavsic Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2023-01-11T21:07:13.000Z","date":"2023-01-10","kind":"sale","acquired":false,"shares":3418,"price":5.24,"value":17910.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 8,325 shares of Common Stock underlying restricted stock units granted to the Reporting Person on January 25, 2022. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $5.12 to $5.37 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":123705,"source":{"system":"sec-edgar","filing":"0001209191-23-002976","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919123002976/doc4.xml","form_type":"4"}},{"id":2211765,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":63177,"kind":"person","name":"Plavsic Mark","position":1,"cik":"0001868719","reported_name":"Plavsic Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2022-07-06T20:04:56.000Z","date":"2022-07-05","kind":"sale","acquired":false,"shares":3719,"price":24.61,"value":91524.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 9,500 shares of Common Stock underlying restricted stock units granted to the Reporting Person on June 14, 2021. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a \"sell to cover\" transaction and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $24.34 to $24.82 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2."}],"balance_after":127123,"source":{"system":"sec-edgar","filing":"0001209191-22-041053","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919122041053/doc4.xml","form_type":"4"}},{"id":2423943,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":63177,"kind":"person","name":"Plavsic Mark","position":1,"cik":"0001868719","reported_name":"Plavsic Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-27T21:37:25.000Z","date":"2022-01-25","kind":"grant","acquired":true,"shares":53058,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option vest in 48 equal month installments beginning on February 1, 2022 such that this option will be fully exercisable on January 1, 2026, subject to the Reporting Person's continued service with the Issuer as of each such date."}],"balance_after":53058,"derivative":{"exercise_price":39.87,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":53058},"source":{"system":"sec-edgar","filing":"0000899243-22-003447","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000089924322003447/doc4.xml","form_type":"4"}},{"id":2423942,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":63177,"kind":"person","name":"Plavsic Mark","position":1,"cik":"0001868719","reported_name":"Plavsic Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2022-01-27T21:37:25.000Z","date":"2022-01-25","kind":"grant","acquired":true,"shares":33302,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Award of restricted stock units that vest with respect to 1/4th of the underlying shares on each of January 8, 2023, January 8, 2024, January 8, 2025 and January 8, 2026, subject to the Reporting Person's continued service with the Issuer as of each such date."}],"balance_after":130842,"source":{"system":"sec-edgar","filing":"0000899243-22-003447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000089924322003447/doc4.xml","form_type":"4"}},{"id":2500630,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":63177,"kind":"person","name":"Plavsic Mark","position":1,"cik":"0001868719","reported_name":"Plavsic Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2021-11-22T22:41:52.000Z","date":"2021-11-19","kind":"grant","acquired":true,"shares":59540,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were granted pursuant to a performance-based restricted stock unit award. The units will vest in three approximately equal installments conditioned upon the achievement, on or before December 31, 2026, of up to three specified late-stage clinical and regulatory milestones of the issuer, so long as the reporting person continues to serve as an employee of the issuer through each milestone achievement."}],"balance_after":97540,"source":{"system":"sec-edgar","filing":"0001209191-21-066162","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919121066162/doc4.xml","form_type":"4"}},{"id":2658685,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":63177,"kind":"person","name":"Plavsic Mark","position":1,"cik":"0001868719","reported_name":"Plavsic Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-22T20:03:49.000Z","date":"2021-06-14","kind":"grant","acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest as to 25% of the underlying shares on June 14, 2022 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date."}],"balance_after":18500,"derivative":{"exercise_price":89.97,"expiration_date":"2031-06-14","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001209191-21-042373","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919121042373/doc4.xml","form_type":"4"}},{"id":2658684,"issuer":{"id":5968,"kind":"organization","name":"FATE THERAPEUTICS INC"},"owners":[{"id":63177,"kind":"person","name":"Plavsic Mark","position":1,"cik":"0001868719","reported_name":"Plavsic Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2021-06-22T20:03:49.000Z","date":"2021-06-14","kind":"grant","acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Exempt grant of restricted stock units pursuant to the Issuer's Inducement Equity Plan.  The units will vest in four annual installments after July 1, 2021, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date."}],"balance_after":38000,"source":{"system":"sec-edgar","filing":"0001209191-21-042373","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434316/000120919121042373/doc4.xml","form_type":"4"}}]}